PMID- 37732114
OWN - NLM
STAT- MEDLINE
DCOM- 20230922
LR  - 20230922
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - Integrated 16S rRNA sequencing and nontargeted metabolomics analysis to reveal 
      the mechanisms of Yu-Ye Tang on type 2 diabetes mellitus rats.
PG  - 1159707
LID - 10.3389/fendo.2023.1159707 [doi]
LID - 1159707
AB  - INTRODUCTION: Yu-Ye Tang (YYT) is a classical formula widely used in treatment of 
      type 2 diabetes mellitus (T2DM). However, the specific mechanism of YYT in 
      treating T2DM is not clear. METHODS: The aim of this study was to investigate the 
      therapeutic effect of YYT on T2DM by establishing a rat model of T2DM. The 
      mechanism of action of YYT was also explored through investigating gut microbiota 
      and serum metabolites. RESULTS: The results indicated YYT had significant 
      therapeutic effects on T2DM. Moreover, YYT could increase the abundance of 
      Lactobacillus, Candidatus_Saccharimonas, UCG-005, Bacteroides and Blautia while 
      decrease the abundance of and Allobaculum and Desulfovibrio in gut microbiota of 
      T2DM rats. Nontargeted metabolomics analysis showed YYT treatment could regulate 
      arachidonic acid metabolism, alanine, aspartate and glutamate metabolism, 
      arginine and proline metabolism, glycerophospholipid metabolism, pentose and 
      glucuronate interconversions, phenylalanine metabolism, steroid hormone 
      biosynthesis, terpenoid backbone biosynthesis, tryptophan metabolism, and 
      tyrosine metabolism in T2DM rats. DISCUSSION: In conclusion, our research showed 
      that YYT has a wide range of therapeutic effects on T2DM rats, including 
      antioxidative and anti-inflammatory effects. Furthermore, YYT corrected the 
      altered gut microbiota and serum metabolites in T2DM rats. This study suggests 
      that YYT may have a therapeutic impact on T2DM by regulating gut microbiota and 
      modulating tryptophan and glycerophospholipid metabolism, which are potential key 
      pathways in treating T2DM.
CI  - Copyright (c) 2023 Ma, Sun, Wang, Wang, Pan, Su, Li, Zhang, Lv and Wang.
FAU - Ma, Ziang
AU  - Ma Z
AD  - Graduate School of Hebei University of Chinese Medicine, Shijiazhuang, China.
FAU - Sun, Wenjuan
AU  - Sun W
AD  - Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine 
      of Hebei Province Affiliated to Hebei University of Chinese Medicine, Cangzhou, 
      China.
FAU - Wang, Lixin
AU  - Wang L
AD  - Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine 
      of Hebei Province Affiliated to Hebei University of Chinese Medicine, Cangzhou, 
      China.
FAU - Wang, Yuansong
AU  - Wang Y
AD  - Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine 
      of Hebei Province Affiliated to Hebei University of Chinese Medicine, Cangzhou, 
      China.
FAU - Pan, Baochao
AU  - Pan B
AD  - Graduate School of Hebei University of Chinese Medicine, Shijiazhuang, China.
FAU - Su, Xiuhai
AU  - Su X
AD  - Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine 
      of Hebei Province Affiliated to Hebei University of Chinese Medicine, Cangzhou, 
      China.
FAU - Li, Hanzhou
AU  - Li H
AD  - College of Integrated Chinese and Western Medicine, Tianjin University of 
      Traditional Chinese Medicine, Tianjin, China.
FAU - Zhang, Hui
AU  - Zhang H
AD  - Graduate School of Hebei University of Chinese Medicine, Shijiazhuang, China.
FAU - Lv, Shuquan
AU  - Lv S
AD  - Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine 
      of Hebei Province Affiliated to Hebei University of Chinese Medicine, Cangzhou, 
      China.
FAU - Wang, Hongwu
AU  - Wang H
AD  - College of Traditional Chinese Medicine, Tianjin University of Traditional 
      Chinese Medicine, Tianjin, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230905
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (RNA, Ribosomal, 16S)
RN  - 8DUH1N11BX (Tryptophan)
RN  - 0 (Glycerophospholipids)
SB  - IM
MH  - Animals
MH  - Rats
MH  - RNA, Ribosomal, 16S
MH  - *Diabetes Mellitus, Type 2/drug therapy/genetics
MH  - Tryptophan
MH  - Metabolomics
MH  - Glycerophospholipids
PMC - PMC10507721
OTO - NOTNLM
OT  - Yu-Ye Tang
OT  - glycerophospholipid metabolism
OT  - gut microbiota
OT  - tryptophan metabolism
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/09/21 06:42
MHDA- 2023/09/22 06:42
PMCR- 2023/01/01
CRDT- 2023/09/21 04:11
PHST- 2023/02/06 00:00 [received]
PHST- 2023/08/21 00:00 [accepted]
PHST- 2023/09/22 06:42 [medline]
PHST- 2023/09/21 06:42 [pubmed]
PHST- 2023/09/21 04:11 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1159707 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 Sep 5;14:1159707. doi: 
      10.3389/fendo.2023.1159707. eCollection 2023.